Clinical observation of low-dose decitabine combined with cytarabine in the treatment of myelodysplastic syndromes
10.3760/cma.j.issn.1009-9921.2016.07.006
- VernacularTitle:小剂量地西他滨联合阿糖胞苷治疗骨髓增生异常综合征临床观察
- Author:
Dayong HUANG
;
Li FU
;
Na WEI
;
Jingshi WANG
;
Jing SHEN
;
Lin WU
;
Yini WANG
;
Hua CUI
;
Zhao WANG
- Publication Type:Journal Article
- Keywords:
Myelodysplastic syndromes;
Decitabine;
Cytarabine
- From:
Journal of Leukemia & Lymphoma
2016;25(7):406-408
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and safety of low-dose decitabine combined with cytarabine for myelodysplastic syndromes (MDS). Methods Clinical data of 15 patients with MDS who took the therapeutic regimen with decitabine combined with cytarabine were collected from January 2012 to January 2015. The clinical efficacy and adverse effects were assessed. Results Among the 15 patients, 4 cases were complete remission (CR), 5 cases were partial remission (PR) and 6 cases were stable disease (SD) and progressive disease (PD). The total effective rate was 60.0 % (9/15). Grade Ⅲ-Ⅳ bone marrow depression occurred in 11 cases with incidence rate of 73.3 % (11/15), and the total incidence rate of infection was 40.0 % (6/15), including lung infection of 26.7 % (4/15). All the infections were controlled after active supportive treatment and anti-infection therapy. No patient died of chemotherapy. Conclusions Low-dose decitabine combined with cytarabine can effectively treat MDS and delay the progress of disease. The patients can tolerate the adverse effects in chemotherapy with a low mortality rate.
